[Asia Economy Reporter Hyunseok Yoo] Nivek announced on the 27th that it is participating in ‘2020 Bio Europe’ to discuss technology transfer of major pipelines with global pharmaceutical companies and to conduct corporate partnering for the development of COVID-19 therapeutics.
The event is scheduled to be held online from October 26 to 29 due to COVID-19. Nivek will engage in technology transfer discussions and corporate partnering related to COVID-19 therapeutics with more than 30 multinational pharmaceutical companies, focusing on its peptide-based platform system, pulmonary fibrosis therapeutics, and inflammatory bowel disease therapeutics.
A Nivek representative stated, “The peptide platform ‘NIPEP-TPP,’ which is currently under joint research and development with global pharmaceutical companies, is the pipeline most likely to show visible results the fastest,” adding, “We plan to discuss the outcomes of the joint research and development conducted so far through this event.”
He continued, “The pulmonary fibrosis therapeutic ‘NIPEP-APF’ and the inflammatory bowel disease therapeutic ‘NIPEP-IBD’ have already completed safety tests through European non-clinical trial institutions (GLP) and efficacy verification through preclinical animal models,” and said, “We are currently discussing technology cooperation and technology transfer with global pharmaceutical companies based in Europe, aiming to enter Phase 1 clinical trials next year.”
Nivek plans to present key research results related to the peptide pipeline through the research status presentation section. Multinational pharmaceutical companies such as Johnson & Johnson, Merck, and Bayer have already expressed great interest in the research results, and corporate partnering and follow-up meetings related to this will also be conducted.
The peptide platform ‘NIPEP-TPP’ has been conducting joint research and development for new drug development with global pharmaceutical companies since last year. It has already completed the supply of preclinical stage candidate substances to global pharmaceutical companies in two phases, and is conducting joint research with global pharmaceutical companies to expand indications along with positive research results.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
